A 224Ra-labeled polyoxopalladate as putative radiopharmaceutical
A 224Ra-labeled polyoxopalladate as putative radiopharmaceutical
Gott, M.; Yang, P.; Kortz, U.; Stephan, H.; Pietzsch, H.-J.; Mamat, C.
Despite its attractive properties, internal targeted alpha therapies using 223/224Ra are limited to bone-seeking applications. As there is no suitable chelator available, the search for new carriers to stably bind Ra2+ and to connect it to biological target molecules is necessary. Polyoxopalladates represent a class of compounds where Ra2+ can be easily introduced into the Pd-POM core during a facile one-pot preparation. Due to the formation of a protein corona the connection to other targeting (bio)macromolecules is possible.
Keywords: Radium; Barium; POM; alpha-therapy
-
Chemical Communications 55(2019), 7631-7634
DOI: 10.1039/C9CC02587A
Cited 29 times in Scopus
Downloads
- Final Draft PDF 1,1 MB Secondary publication
Permalink: https://www.hzdr.de/publications/Publ-29051
Publ.-Id: 29051